Olive Leaf Extracts in the Control of Hypertension

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 500 participants.

Also called NCT05636826

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 500 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05636826
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Tunisia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05636826. Randomized; single masking; primary purpose treatment. Start 2023-12-30 (actual); primary completion 2024-11-22 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Olive Leaf Extracts in the Control of Hypertension
Acronym
Atherolive
Condition
Hypertension
Intervention (Drug)
atherolive-drug
Intervention (Drug)
Placebo Atherolive
Lead sponsor
University of Monastir (class: other)

Record details

Record id
cardio:ct-nct05636826
Content hash
9e72504b8714764a75d528706fb798a7243b096e3ad7868c61b01f3e4ddc1749